Evidence map›Paper›PMID 32968487›Full record

ArticleJournal of pharmaceutical policy and practice2020

The use of remdesivir outside of clinical trials during the COVID-19 pandemic.

Vesa Halimi, Armond Daci, Nevenka Ridova, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce, Aleksandar Dimovski, Aleksandra Grozdanova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Vesa HalimiFaculty of Pharmacy, University Ss. Cyril and Methodius University, Skopje, North Macedonia.
Armond DaciDepartment of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo.
Nevenka RidovaUniversity Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius University, Skopje, North Macedonia.
Irina Panovska-StavridisUniversity Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius University, Skopje, North Macedonia.
Milena StevanovicUniversity Clinic of Infection Diseases and Febrile Conditions, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Venko FilipceUniversity Clinic for Neurosurgery, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Aleksandar DimovskiFaculty of Pharmacy, University Ss. Cyril and Methodius University, Skopje, North Macedonia.
Aleksandra GrozdanovaFaculty of Pharmacy, University Ss. Cyril and Methodius University, Skopje, North Macedonia.ORCID 0000-0002-0098-8691
Ss. Cyril and Methodius University in Skopje · MKUniversity of Prishtina · XK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investigated through clinical research (clinical trials) and clinical practice (compassionate use, expanded access, early access scheme, and emergency use). Currently, remdesivir approval status differs between states. This paper aims to review and analyze regulatory approaches for accessing and investigating remdesivir, by communicating regulatory variability between countries in terms of terminology, modalities, and protocols.

Indexed as

Clinical practiceClinical trialsCompassionate useConditional approvalCOVID-19Early access schemeEmergency useExpanded accessRemdesivir

Identifiers

PMID32968487
PMCPMC7503054
OpenAlexW3087049974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.